Cystaran®
Cysteamine 0.44% · ophthalmic solution
Misc.
Approved uses
Corneal cystine crystal accumulation in cystinosis
1 drop in each eye every waking hour; discard 1 week after the foil and bottle are opened
Corneal crystals dissolve over 8 to 41 months, so counsel months rather than weeks.
Contraindications
None.
0.44% (4.4 mg/mL cysteamine, 6.5 mg/mL cysteamine hydrochloride), 15 mL bottle, frozen-storage and refrigerated-storage presentations
Cystine-depleting agent: converts cystine to cysteine and to cysteine-cysteamine mixed disulfides, reducing corneal cystine crystal accumulation. Systemic exposure after ophthalmic administration is expected to be negligible compared to oral administration, since the total daily ophthalmic dose is less than 2% of the recommended oral daily dose.
Warnings & Precautions
- Benign intracranial hypertension: Reported with oral cysteamine and resolved with added diuretic therapy; every reported case with the ophthalmic route was in a patient concurrently on the oral drug.
- Contact lens use: Benzalkonium chloride may be absorbed by soft contact lenses; remove lenses before instillation, and they may be reinserted 15 minutes after.
- Dropper contamination: Do not touch the tip to the eyelids, surrounding areas, or any surface; keep the bottle tightly closed when not in use.
- In-use stability: Solution is only stable 1 week after the foil and bottle are opened; record the discard date and discard at 1 week even if medication remains.
- Cold chain: The frozen presentation needs roughly 24 hours to thaw before the first dose and must never be refrozen; the thawed bottle needs no refrigeration between doses during its week of use.
- Topical ophthalmic use: This product is for topical ophthalmic use.
Common Side Effects
The most common adverse reactions, at an incidence of approximately 10% or greater, are sensitivity to light, redness, eye pain/irritation, headache and visual field defects. These safety data reflect exposure in controlled clinical trials of six months to 19 years duration in approximately 300 patients.
Pregnancy: No adequate and well controlled studies of ophthalmic cysteamine in pregnant women; oral cysteamine through organogenesis in rats was teratogenic at 86 to 345 times the recommended human ophthalmic dose (intrauterine death, cleft palate, kyphosis, ventricular septal defects, microcephaly, exencephaly, growth deficits). Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: No data on human milk, the breastfed infant, or milk production; cysteamine is present in the milk of orally dosed lactating rats. It is not known whether measurable levels of cysteamine would be present in maternal milk following topical ocular administration.
Safety and effectiveness established in pediatric patients.